ventilatorassoci
respiratori
infect
vari
may
manifest
tracheobronch
vat
ventilatorassoci
pneumonia
vap
vari
usual
caus
bacteria
colon
patient
oropharynx
stomach
enter
lower
respiratori
tract
around
endotrach
tube
cuff
lumen
initi
antibiot
manag
vari
complic
delay
identif
antibiot
sensit
data
wide
spectrum
potenti
pathogen
increasingli
multidrugresist
mdr
placement
endotrach
tube
facilit
bacteri
entri
lower
respiratori
tract
impair
bacteri
clearanc
host
defens
increas
risk
vap
differenti
vari
colon
initi
base
presenc
clinic
sign
symptom
suggest
infect
fever
purul
sputum
elev
peripher
leukocyt
count
microbiolog
data
also
critic
specif
criteria
vari
sampl
method
type
sampl
exampl
endotrach
aspir
ea
readili
avail
intub
patient
bronchoalveolar
lavag
bal
protect
specimen
brush
psb
techniqu
gramstain
ea
might
assist
diagnosi
vari
employ
mani
hospit
intens
care
unit
presenc
polymorphonuclear
leukocyt
pmnl
indic
possibl
inflamm
infect
wherea
inform
bacteri
morpholog
may
suggest
like
pathogen
cultur
ea
either
quantit
qea
semiquantit
method
sqea
use
distinguish
colon
vari
identif
sensit
data
usual
avail
within
hour
lack
standard
definit
diagnosi
vat
vap
base
ea
sampl
creat
confus
clinician
use
either
qea
sqea
method
versu
bronchoscop
b
nonbronchoscop
nb
bal
psb
sampl
purpos
articl
highlight
epidemiolog
pathogenesi
diagnosi
manag
strategi
vari
author
primari
aim
clarifi
current
diagnost
criteria
diagnos
vat
vap
versu
tracheal
colon
underscor
specif
clinic
microbiolog
clue
could
lead
earlier
appropri
antibiot
treatment
vari
epidemiolog
vat
vap
defin
infect
occur
hour
intub
earli
vap
occur
within
first
day
intub
lateonset
vap
occur
day
commonli
caus
mdr
pathogen
carri
higher
morbid
mortal
tabl
report
crude
mortal
rate
vap
rang
health
care
cost
estim
per
episod
recent
studi
outcom
intens
care
unit
icu
patient
receiv
longterm
ventil
icu
duke
univers
surviv
rate
year
patient
depend
care
mani
patient
multipl
admiss
spectrum
transit
care
facil
estim
cost
million
dollar
per
patient
medic
surgic
patient
diagnos
vat
also
experi
significantli
longer
length
icu
stay
durat
mechan
ventil
possibl
progress
vap
incid
vat
europ
rang
depend
popul
studi
recent
studi
unit
state
use
differ
model
definit
report
incid
vat
compar
incid
vap
howev
patient
vat
progress
vap
frequent
pathogen
isol
patient
vat
vap
shown
tabl
past
year
increas
incid
infect
due
mdr
gramneg
pathogen
pseudomona
aeruginosa
acinetobact
baumannii
stenotrophomona
maltophilia
enterobacteriacea
escherichia
coli
klebsiella
pneumonia
addit
also
dramat
increas
infect
due
methicillinresist
staphylococcu
aureu
mrsa
like
continu
vari
may
rare
caus
pathogen
regularli
identifi
routin
ea
bal
cultur
gram
stain
legionella
pneumophila
anaerob
bacteria
coagulaseneg
staphylococci
virus
influenza
b
respiratori
syncyti
viru
herp
simplex
viru
coronaviru
cytomegaloviru
reactiv
mycobacterium
tuberculosi
rare
fungal
pathogen
cryptococcu
neoforman
aspergillu
fumigatu
candida
speci
occur
rare
except
immunocompromis
patient
understand
pathogenesi
vat
vap
essenti
establish
principl
strategi
therapi
prevent
fig
intub
mechan
ventil
increas
risk
bacteri
pneumonia
sixfold
endotrach
tube
ett
oronasogastr
tube
ognt
facilit
bacteri
entri
lower
respiratori
tract
tracheal
colon
may
progress
intub
patient
vat
vap
fig
bacteria
usual
enter
lower
respiratori
tract
leakag
around
ett
cuff
via
ett
lumen
inflat
ett
cuff
prevent
exit
bacteria
secret
lower
airway
increas
need
manual
tracheabronchi
suction
infect
secret
furthermor
ett
biofilmencas
bacteria
may
also
contribut
lower
airway
infect
biofilm
emboli
number
type
virul
bacteri
pathogen
enter
trachea
well
host
defens
import
factor
diseas
progress
addit
wide
spectrum
potenti
pathogen
bacteri
virul
may
vari
within
bacteri
speci
mechan
host
defens
mucu
cilia
polymorphonuclear
leukocyt
pmnl
macrophag
respect
cytokin
work
conjunct
humor
antibodi
eg
immunoglobulin
igm
igg
iga
complement
prevent
progress
colon
vat
vap
similar
differ
diagnost
criteria
vat
vap
summar
tabl
fig
note
consider
overlap
clinic
definit
term
fever
leukocytosi
purul
sputum
chang
oxygen
clinician
investig
reli
combin
factor
includ
clinic
pulmonari
infect
score
cpi
score
least
suggest
marker
vap
clinic
differenti
vat
vap
difficult
due
current
note
overlap
microbiolog
criteria
endotrach
aspir
use
diagnosi
contrast
differ
criteria
bronchoalveolar
lavag
protect
specimen
brush
use
abbrevi
ard
acut
respiratori
distress
syndrom
bal
bronchoalveolar
lavag
chf
congest
heart
failur
ct
computer
tomographi
fio
inspir
oxygen
concentr
pao
partial
pressur
oxygen
arteri
blood
pmnl
polymorphonuclear
leukocyt
psb
protect
specimen
brush
vap
ventilatorassoci
pneumonia
vari
ventilatorassoci
respiratori
infect
vat
ventilatorassoci
tracheobronch
definit
overlap
infect
ea
use
microbiolog
diagnosi
contrast
vat
vap
requir
radiograph
evid
new
infiltr
may
difficult
assess
especi
patient
preexist
infiltr
sever
congest
heart
failur
acut
respiratori
distress
syndrom
ard
fig
unfortun
portabl
chest
radiograph
often
poor
qualiti
reduc
sensit
concern
specif
well
particularli
patient
preexist
pulmonari
infiltr
due
noninfecti
caus
nseir
colleagu
report
ventil
studi
patient
abnorm
chest
radiograph
time
admiss
icu
similar
problem
chest
radiograph
interpret
specif
note
other
data
suggest
computer
tomographi
ct
lung
scan
provid
better
resolut
also
limit
readili
avail
mani
icu
interpret
chest
infiltr
critic
ill
patient
could
improv
use
ct
lung
scan
may
impract
mani
icu
patient
addit
dose
radiat
exposur
high
equival
greater
portabl
chest
radiograph
base
clinic
radiolog
reserv
microbiolog
criteria
becom
cornerston
diagnosi
vat
vap
due
aerob
bacteri
pathogen
see
tabl
standard
criteria
microbiolog
diagnosi
vap
exist
bbal
cfuml
nbbal
cfuml
well
bpsb
cfuml
techniqu
see
fig
tabl
tabl
smear
ea
cytospin
bal
psb
specimen
examin
pmnl
bacteria
mani
pmnl
along
bacteria
fig
clue
diagnosi
ventilatorassoci
respiratori
infect
vari
includ
tracheobronch
vat
pneumonia
vap
clinic
clue
common
vari
vat
vap
radiolog
clue
may
help
discrimin
vap
vat
base
presenc
absenc
new
pulmonari
infiltr
comparison
microbiolog
clue
differ
depend
diagnost
methodolog
employ
note
signific
growth
pathogen
bronchoscopicbronchoalveolar
lavag
bbal
cfuml
nonbronchoscop
bal
nbal
cfuml
protect
specimen
brush
psb
cfuml
diagnost
vap
absenc
signific
growth
bbal
cfuml
nbal
cfuml
psb
cfuml
consist
vat
colon
endotrach
aspir
ea
use
diagnosi
difficult
discrimin
vat
vap
help
distinguish
colon
infect
vari
suggest
infect
presenc
bacteria
gram
stain
ea
correspond
bacteri
coloni
count
greater
coloni
form
unit
cfu
ml
gram
stain
provid
clue
bacteri
morpholog
cocci
bacilli
morpholog
arrang
cluster
vs
pair
chain
whether
bacteria
belong
gramposit
gramneg
group
absenc
pmnl
reduc
likelihood
bacteri
infect
presenc
mani
suggest
vari
bacteria
smear
absenc
recent
treatment
antibiot
suggest
noninfecti
nonbacteri
caus
confus
less
standard
quantit
cultur
assess
ea
sampl
mani
microbiolog
laboratori
use
sqea
method
report
growth
bacteri
pathogen
isol
rare
moder
mani
shown
fig
cultur
growth
usual
repres
colon
presenc
growth
consist
vari
vat
vap
laboratori
use
qea
report
result
number
cfuml
specimen
clearcut
valu
diagnosi
vari
differ
provid
use
differ
threshold
eg
vs
cfuml
quantit
cultur
less
valu
suggest
colon
sever
combin
clinic
microbiolog
criteria
exist
diagnosi
vat
vap
vari
consider
merit
debat
decad
diagnosi
vat
vap
qea
cfuml
propos
french
investig
correspond
well
moder
mani
growth
sqea
mani
bacteria
gram
stain
dalla
colleagu
suggest
threshold
qea
greater
equal
cfuml
sqea
moder
mani
growth
also
correl
fewtomoder
bacteria
present
gramstain
smear
ea
elebiari
colleagu
report
although
qea
greater
cfuml
good
sensit
specif
qea
less
specif
psb
bal
diagnos
vap
nseir
use
qea
result
greater
cfuml
diagnosi
vat
better
specif
cfuml
lack
accept
univers
definit
microbiolog
benchmark
assess
qea
sqea
unfortun
often
base
sensit
specif
criteria
compar
gold
standard
remain
elus
specif
definit
critic
patient
care
also
surveil
assess
efficaci
prevent
strategi
public
report
improv
patient
outcom
reduc
health
care
cost
serial
ea
use
microbiolog
surveil
identifi
like
pathogen
antibiot
sensit
develop
vari
ea
gramstain
cultur
data
could
also
predictor
patient
risk
vat
vap
posit
surveil
ea
cultur
enabl
distinct
colon
infect
facilit
earlier
appropri
antibiot
therapi
improv
patient
outcom
fig
three
studi
examin
use
serial
respiratori
surveil
cultur
collect
differ
time
michel
colleagu
obtain
qea
twice
weekli
intub
cohort
compar
cultur
bal
perform
time
vap
caus
organ
identifi
prior
qea
studi
patient
vap
commonli
lateonset
offend
organ
p
aeruginosa
deputdt
colleagu
use
weekli
qea
detect
vap
due
mdr
pathogen
found
vap
due
mdr
pathogen
episod
surveil
cultur
led
appropri
antibiot
therapi
patient
similar
studi
bal
confirm
vap
hayon
colleagu
report
qea
surveil
cultur
identifi
least
one
pathogen
isol
bal
highest
predict
valu
cultur
obtain
within
hour
vap
diagnosi
final
yang
colleagu
use
daili
qea
cultur
identifi
patient
mdr
p
aeruginosa
report
colon
patient
like
develop
vap
studi
clearli
need
expand
confirm
result
differ
patient
popul
also
need
look
optim
interv
surveil
cultur
provid
appropri
time
therapi
improv
patient
outcom
see
fig
vat
may
precursor
overlap
vap
treatment
provid
opportun
earlier
intervent
target
rather
empir
antibiot
therapi
sever
observ
random
vat
studi
publish
summar
acourt
colleagu
studi
tracheal
colon
mechan
ventil
patient
use
serial
quantit
nonbronchoscop
bal
sampl
report
increas
lower
respiratori
tract
colon
time
appear
peak
day
onset
clinic
sign
vap
prospect
observ
cohort
medic
surgic
patient
nseir
colleagu
vat
associ
increas
length
icu
stay
mechan
ventil
day
higher
mortal
medic
surgic
icu
patient
later
studi
quantit
qea
cfuml
colon
observ
cfuml
infect
consid
therapi
note
differ
gram
stain
cultur
criteria
ea
sputum
sampl
examin
quantit
qea
semiquantit
sqea
method
diagnost
criteria
sampl
obtain
bronchoscop
b
nonbronchoscop
n
bronchoalveolar
lavag
bal
protect
specimen
brush
psb
abbrevi
cfu
coloni
form
unit
ea
endotrach
aspir
hpf
high
power
field
microscop
lpf
low
power
field
microscop
vap
ventilatorassoci
pneumonia
vari
ventilatorassoci
respiratori
infect
vat
ventilatorassoci
tracheobronch
patient
chronic
obstruct
pulmonari
diseas
copd
author
report
patient
vat
compar
match
control
significantli
lower
median
day
mechan
ventil
icu
day
antibiot
therapi
appear
protect
vap
later
prospect
observ
casecontrol
studi
patient
vat
patient
treat
antibiot
significantli
fewer
day
mechan
ventil
icu
stay
differ
note
mortal
rate
two
random
studi
antibiot
therapi
vat
recent
conduct
studi
popul
definit
vat
intervent
differ
nseir
colleagu
report
result
control
unblind
trial
patient
clinic
diagnosi
vat
vat
defin
qea
greater
cfuml
infiltr
chest
radiograph
patient
random
receiv
target
intraven
antibiot
therapi
versu
delay
therapi
antibiotictr
group
display
better
outcom
mechan
ventilationfre
day
median
vs
day
p
lower
icu
mortal
vs
p
signific
decreas
vap
vs
p
bacteri
pathogen
identifi
studi
group
support
concept
vat
appear
progress
vap
patient
import
limit
studi
includ
low
number
patient
imbal
number
patient
random
group
lack
independ
blind
evalu
endpoint
interpret
chest
radiograph
exclud
earli
vap
palmer
colleagu
perform
doubleblind
random
placebocontrol
studi
medic
icu
micu
surgic
icu
sicu
patient
compar
aerosol
antibiot
treatment
gentamicin
everi
hour
gramneg
bacilli
present
vancomycin
everi
hour
gramposit
bacteria
detect
mix
infect
day
extub
n
versu
salin
placebo
n
vat
defin
product
least
ml
purul
ea
period
gram
stain
demonstr
bacteria
system
antibiot
given
discret
treat
physician
frequent
prescrib
group
compar
placebo
group
aerosol
antibiot
group
significantli
better
outcom
manifest
lower
rate
clinic
sign
symptom
vap
faster
wean
ventil
reduc
number
mdr
pathogen
lower
use
system
antibiot
endpoint
p
notabl
limit
studi
includ
definit
vat
lack
qea
high
number
patient
prior
vap
lack
data
radiograph
sign
vap
small
number
studi
patient
potenti
confound
effect
use
system
antibiot
differ
result
report
dalla
colleagu
retrospect
studi
vat
vap
medic
surgic
icu
patient
dallla
colleagu
report
vat
occur
less
commonli
vap
use
ea
cutoff
cfuml
patient
mdr
pathogen
patient
diagnos
vat
frequent
progress
vap
vat
vap
patient
similar
mortal
vs
conclus
may
relat
definit
use
vat
vap
wellknown
limit
portabl
chest
radiograph
interpret
defin
vap
lack
surveil
cultur
retrospect
chart
review
diagnosi
vat
vap
bbalnbalpsb
clearli
delin
howev
ea
use
diagnosi
discrimin
vap
vat
almost
imposs
low
sensit
specif
clinic
radiolog
find
overlap
microbiolog
criteria
howev
quantit
semiquantit
ea
discrimin
colon
fig
model
use
quantit
q
semiquantit
sq
endotrach
aspir
ea
initi
arget
rather
empir
antibiot
therapi
ventilatorassoci
respiratori
infect
vari
includ
tracheobronchitii
vat
pneumonia
vap
goal
earli
target
appropri
antibiot
therapi
improv
patient
outcom
term
reduc
mortal
morbid
health
care
cost
infect
vari
term
clearli
discrimin
colon
infect
due
vat
vap
due
limit
avail
bbalnbal
psb
mani
icu
ea
commonli
use
diagnosi
vap
author
emphas
import
quantit
semiquantit
ea
criteria
assess
vari
trigger
point
consid
initi
earli
appropri
antibiot
therapi
exampl
growth
klebsiella
speci
sqea
qea
less
like
repres
colon
like
requir
treatment
antibiot
howev
least
caveat
appli
recommend
patient
critic
ill
eg
shock
cultur
perform
within
hour
patient
receiv
antibiot
within
hour
cultur
obtain
addit
recommend
pertain
bacteri
pathogen
associ
vari
summar
tabl
earli
appropri
antibiot
therapi
emphas
american
thorac
societi
infecti
diseas
societi
america
guidelin
associ
improv
patient
outcom
guidelin
recommend
broadspectrum
empir
antibiot
therapi
cultur
antibiot
sensit
data
avail
deescal
antibiot
base
microbiolog
data
howev
intub
patient
use
surveil
ea
may
provid
earlier
inform
colon
mdr
pathogen
could
use
target
antibiot
therapi
approach
could
reduc
inappropri
antibiot
therapi
reduc
overus
antibiot
result
select
mdr
pathogen
improv
clinic
outcom
reduc
health
care
cost
clinic
definit
diagnosi
vat
vap
lack
specif
differenti
may
difficult
definit
import
guid
clinician
antibiot
treatment
initi
antibiot
use
vari
term
indic
infect
deserv
consider
antibiot
therapi
surveil
cultur
identifi
pathogen
help
clinician
initi
earlier
target
antibiot
therapi
purpos
commun
highlight
import
microbiolog
clue
aid
clinician
distinguish
infect
colon
author
goal
drive
rate
vari
emphas
prevent
strategi
decreas
rate
vat
vap
strategi
improv
outcom
includ
earli
identif
infect
avoid
intub
remov
endotrach
tube
soon
possibl
use
sedat
vacat
treat
infect
earli
limit
inappropri
antibiot
use
